You are in Herbal Remedies for Heart and Circulation > Danshen Pian
Detailed Specification
Menu of Categories
Chinese Medicine
Chinese Herbal Medicine
Chinese Medicine Pharmacy
Traditional Chinese Medicine
Leading Brand Chinese Herbal Medicine
Chinese Tea
Natural Health Supplements
Herbal Remedies
Natural Cures
Since 2009
50 tablet box
£9.50
Danshen Pian
Manufacturer : Tongrentang Pharmaceutical Company
Packing : 50 tablet box
Pharmaceutical Ingredients : Chinese Herbal
Product Category : Heart and Circulation
Code CT0247
3 box reserve
£24.50
Code CT3247
Chinese Pinyin Name : Danshen Pian.
Product Category : Heart and Circulatiion.
Functions and Indications : Blood circulation. For the common symptoms of angina pectoris, chest tightness, tingling in the heart or surrounding area due to qi stagnation.
Properties : This product is a film-coated tablet, after coating removal, brown colour, gas aromatic bitter taste.
Main Ingredients : Miltiorrhiza, Panax, Ginseng, Borneol.
Specification : Each table weight 0.32g.
Usage and Dosage : Oral, take 3 tablets up to 3 times a day.
Note :
Packing : 50 tablet box.
Storage : Keep sealed in a dry cool place, shelf life 36 months.
Listed : The People's Republic of China Pharmacopoeia 2005 Edition 1.
Approval Licence Number : Z11021185.
Product Category : Heart and Circulatiion.
Functions and Indications : Blood circulation. For the common symptoms of angina pectoris, chest tightness, tingling in the heart or surrounding area due to qi stagnation.
Properties : This product is a film-coated tablet, after coating removal, brown colour, gas aromatic bitter taste.
Main Ingredients : Miltiorrhiza, Panax, Ginseng, Borneol.
Specification : Each table weight 0.32g.
Usage and Dosage : Oral, take 3 tablets up to 3 times a day.
Note :
- Avoid eating spicy, cold or greasy food at the same time as medication.
- If the symptoms are not relieved go to a hospital.
- Do not take during pregnancy.
Packing : 50 tablet box.
Storage : Keep sealed in a dry cool place, shelf life 36 months.
Listed : The People's Republic of China Pharmacopoeia 2005 Edition 1.
Approval Licence Number : Z11021185.
Salvia miltiorrhiza Bunge, also known as Danshen in Chinese, has been widely used to treat cardiovascular diseases (CVD) in China and other Asia countries. Here, we summarize literatures of the historical traditional Chinese medicine (TCM) interpretation of the action of Salvia miltiorrhiza, its use in current clinical trials, its main phytochemical constituents and its pharmacological findings by consulting Pubmed, China Knowledge Resource Integrated, China Science and Technology Journal, and the Web of Science Databases. Since 2000, 39 clinical trials have been identified that used S. miltiorrhiza in TCM prescriptions alone or with other herbs for the treatment of patients with CVD. More than 200 individual compounds have been isolated and characterized from S. miltiorrhiza, which exhibited various pharmacological activities targeting different pathways for the treatment of CVD in various animal and cell models. The isolated compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-CVD drugs. Meanwhile, there are also some rising concerns of the potential side effects and drug-drug interactions of this plant. The insights gained from this study will help us to better understanding of the actions of this herb for management of cardiovascular disorders. As an herb of red root, S. miltiorrhiza will act as a potential red light to prevent the development of CVD.
Introduction
Salvia miltiorrhiza Bunge, also known as red sage or Danshen (Chinese Pinyin name), is a perennial plant (Fig. ?1A1A) in the genus Salvia of the mint family, Lamiaceae [1]. Its roots are highly valued as a ?super grade herb (herbs lacking observable toxicity)? in the Shennong?s Herbal Classic of Materia Medica (Shennong Bencao Jing) written during the reign of the Qin and Han dynasties (221 BC to 220 AD), and has been clinically used for more than 2000 years. Following this first record, S. miltiorrhiza was well described in classical traditional Chinese medicine (TCM) works such as in the Compendium of Materia Medica (Bencao Gangmu, Ming dynasty, 1596 AD). In the textbooks of academic TCM, S. miltiorrhiza is characterized as a common drug for promoting blood circulation and removing blood stasis. The herb has been officially recorded in the Chinese pharmacopoeia since 1953. According to the Chinese pharmacopoeia [2], S. miltiorrhiza is the only official source of Salvia Radix & Rhizoma (Danshen) [3]. Phytochemical studies have shown that S. miltiorrhiza contained a large number of lipophilic diterpenoids (such as various tanshinone analogues), hydrophilic phenolic compounds (such as salvianolic acids), flavonoids, and triterpenoids) [4-7]. S. miltiorrhiza has traditionally been used in the treatment of CVD [8], such as atherosclerosis [9], thrombosis [10], and angina pectoris [11, 12]. And data about clinical information of hospitalized patients and outpatients with coronary artery disease and hypertension have demonstrated that S. miltiorrhiza was top-ranked (63.10% and 17.1%, respectively) among all the clinical administered drugs in Beijing, Tianjin [13] and Taiwan [14].
Introduction
Salvia miltiorrhiza Bunge, also known as red sage or Danshen (Chinese Pinyin name), is a perennial plant (Fig. ?1A1A) in the genus Salvia of the mint family, Lamiaceae [1]. Its roots are highly valued as a ?super grade herb (herbs lacking observable toxicity)? in the Shennong?s Herbal Classic of Materia Medica (Shennong Bencao Jing) written during the reign of the Qin and Han dynasties (221 BC to 220 AD), and has been clinically used for more than 2000 years. Following this first record, S. miltiorrhiza was well described in classical traditional Chinese medicine (TCM) works such as in the Compendium of Materia Medica (Bencao Gangmu, Ming dynasty, 1596 AD). In the textbooks of academic TCM, S. miltiorrhiza is characterized as a common drug for promoting blood circulation and removing blood stasis. The herb has been officially recorded in the Chinese pharmacopoeia since 1953. According to the Chinese pharmacopoeia [2], S. miltiorrhiza is the only official source of Salvia Radix & Rhizoma (Danshen) [3]. Phytochemical studies have shown that S. miltiorrhiza contained a large number of lipophilic diterpenoids (such as various tanshinone analogues), hydrophilic phenolic compounds (such as salvianolic acids), flavonoids, and triterpenoids) [4-7]. S. miltiorrhiza has traditionally been used in the treatment of CVD [8], such as atherosclerosis [9], thrombosis [10], and angina pectoris [11, 12]. And data about clinical information of hospitalized patients and outpatients with coronary artery disease and hypertension have demonstrated that S. miltiorrhiza was top-ranked (63.10% and 17.1%, respectively) among all the clinical administered drugs in Beijing, Tianjin [13] and Taiwan [14].
Miltiorrhiza (Danshen) : A Potential Red Light to the Development of
Cardiovascular Diseases
Cardiovascular Diseases
Article published by PMC Feb 2017.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421141/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421141/
Chinese Herbal Medicine
Website www.china-herbal.co.uk - Email mail@china-herbal.co.uk
Copyright (C) 2010 - 2020 Global Health Foods. All rights reserved
Chinese Medicine, Herbal Medicine, Chinese Herbal Medicine